Dishman Carbogen Amcis Limited (BOM:540701)

Market Cap	23.90B -47.0%
Revenue (ttm)	29.01B +0.2%
Net Income	161.60M -84.5%
EPS	1.03 -84.7%
Shares Out	n/a
PE Ratio	147.92
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,135
Open	154.80
Previous Close	151.15
Day's Range	151.60 - 155.95
52-Week Range	129.00 - 306.75
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments. The company offers cholesterol and vitamin D analogs; soft gel capsules and formulations; intermediate and active pharmaceutical ingredients (APIs) which cover specific therapeutic areas, such as anesthetics, and contrast media agents for diagnostics, ophthalmic treatments, laxatives, and organophosph...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1983
• Employees: 934
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540701

Financial Performance

In fiscal year 2026, Dishman Carbogen Amcis's revenue was 29.32 billion, an increase of 8.13% compared to the previous year's 27.12 billion. Earnings were 974.50 million, an increase of 2907.72%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 7, 2026

Data Sources Report a data error